Key Highlights

  • Shares trading up 5.90%, adding $0.79 to reach $14.17
  • Move reflects continued bullish analyst sentiment following Phase 3 psilocybin therapy data
  • Stock carries a 'Moderate Buy' consensus rating from 17 brokerages with an average price target of $23.36
  • HC Wainwright reiterated a Buy rating with a $65 price target despite trimming near-term EPS estimates
  • Company continues to weigh a wider-than-expected third-quarter loss against progress toward a potential first-half 2027 FDA approval
  • Cash position of approximately $433 million supports continued pipeline investment

Bullish Analyst Sentiment Continues to Drive Shares

COMPASS Pathways (NASDAQ:CMPS) shares rose sharply today, up 5.90% to $14.17, as analyst sentiment remained bullish following the company's Phase 3 psilocybin therapy data and continued progress toward a potential first-half 2027 FDA approval. The stock received a 'Moderate Buy' consensus rating from 17 brokerages with an average price target of $23.36, and HC Wainwright reiterated a Buy rating with a $65 price target despite trimming near-term EPS estimates.

COMPASS Pathways plc is a London-headquartered clinical-stage biotechnology company, with additional offices in New York and San Francisco, dedicated to accelerating patient access to evidence-based innovation in mental health care. Led by CEO Kabir Nath, the company is pioneering COMP360, a proprietary, high-purity synthetic psilocybin formulation administered alongside structured psychological support, which has received FDA Breakthrough Therapy Designation for treatment-resistant depression.

Investors Weigh Wider Losses Against Regulatory Progress

COMP360 has progressed through Phase III trials for treatment-resistant depression and is also being evaluated in Phase II studies for post-traumatic stress disorder and anorexia nervosa. As investors continue to weigh the company's wider-than-expected third-quarter loss against ongoing regulatory progress, COMPASS Pathways continues to advance its pipeline aimed at addressing serious unmet needs for patients not helped by existing mental health treatments, supported by a cash position of approximately $433 million.

Conclusion

COMPASS Pathways' 5.90% gain today reflects sustained bullish analyst sentiment tied to the company's Phase 3 psilocybin therapy program and its path toward a potential 2027 FDA approval decision. With a substantial cash position supporting continued clinical development and analyst price targets well above current trading levels, the stock's next moves will likely hinge on continued regulatory and trial progress for COMP360 across its expanding indication set.